{"id":33788,"date":"2020-08-27T16:58:42","date_gmt":"2020-08-27T15:58:42","guid":{"rendered":"https:\/\/www.biotechpharmasummit.com\/?page_id=33788"},"modified":"2021-03-19T09:03:57","modified_gmt":"2021-03-19T09:03:57","slug":"drug-delivery-formulation-2019-speakers","status":"publish","type":"page","link":"https:\/\/www.biotechpharmasummit.com\/index.php\/drug-delivery-formulation-2019-speakers\/","title":{"rendered":"Drug Delivery & Formulation 2019 Speakers"},"content":{"rendered":"
\n

\n\tOur
Speakers (A-Z)
\n\t<\/h2>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Andreas_Bernkop_Schnurch_BioTEch_Pharma_Summit_Thiomatrix_1.png 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Andreas_Bernkop_Schnurch_BioTEch_Pharma_Summit_Thiomatrix_1-201×300.png 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Andreas_Bernkop_Schnurch_BioTEch_Pharma_Summit_Thiomatrix_1-686×1024.png 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Andreas_Bernkop_Schnurch_BioTEch_Pharma_Summit_Thiomatrix_1-768×1146.png 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Andreas_Bernkop_Schnurch_BioTEch_Pharma_Summit_Thiomatrix_1-630×940.png 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Andreas_Bernkop_Schnurch_BioTEch_Pharma_Summit_Thiomatrix_1-420×627.png 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Andreas_Bernkop_Schnurch_BioTEch_Pharma_Summit_Thiomatrix_1-315×470.png 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33872″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/drug-delivery-formulation-2019-speakers\/andreas-bernkop-schnurch\/andreas_bernkop_schnurch_biotech_pharma_summit_thiomatrix_1\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Andreas_Bernkop_Schnurch_BioTEch_Pharma_Summit_Thiomatrix_1.png” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}” data-image-title=”Andreas_Bernkop_Schnurch_BioTEch_Pharma_Summit_Thiomatrix_1″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Andreas_Bernkop_Schnurch_BioTEch_Pharma_Summit_Thiomatrix_1-201×300.png” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Andreas_Bernkop_Schnurch_BioTEch_Pharma_Summit_Thiomatrix_1-686×1024.png”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tAndreas Bernkop-Schnu\u0308rch\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
CSO at Thiomatrix Forschungs- Beratungs GmbH<\/h5>\n

\n\t\t\t\n\tAdvanced nanoemulsions: Key to high bioavailability of class 3 drugs\n\t\t\t<\/a>\n\t<\/h3>\n\t

Andreas Bernkop-Schn\u00fcrch is a leading scientist in the field of drug delivery focusing on mucoadhesive polymers such as in particular thiomers, non-invasive peptide delivery systems and nanoemulsions.<\/p>\n

He is chairman at the Department of Pharmaceutical Technology at the University of Innsbruck, Austria and CSO of the drug delivery company ThioMatrix GmbH. He has published more than 500 reseach and review articles.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Bonestebe_Audrey_Sanofi_France_BioTech_Pharma_Summit_Profile_1.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Bonestebe_Audrey_Sanofi_France_BioTech_Pharma_Summit_Profile_1-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Bonestebe_Audrey_Sanofi_France_BioTech_Pharma_Summit_Profile_1-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Bonestebe_Audrey_Sanofi_France_BioTech_Pharma_Summit_Profile_1-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Bonestebe_Audrey_Sanofi_France_BioTech_Pharma_Summit_Profile_1-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Bonestebe_Audrey_Sanofi_France_BioTech_Pharma_Summit_Profile_1-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Bonestebe_Audrey_Sanofi_France_BioTech_Pharma_Summit_Profile_1-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33866″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/drug-delivery-formulation-2019-speakers\/audrey-bonestebe\/sanofi-rd-vitry-2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Bonestebe_Audrey_Sanofi_France_BioTech_Pharma_Summit_Profile_1.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"Jean Chiscano","camera":"","caption":"","created_timestamp":"1554382686","copyright":"Jean Chiscano","focal_length":"0","iso":"0","shutter_speed":"0","title":"SANOFI R&D Vitry","orientation":"1"}” data-image-title=”SANOFI R&amp;D Vitry” data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Bonestebe_Audrey_Sanofi_France_BioTech_Pharma_Summit_Profile_1-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Bonestebe_Audrey_Sanofi_France_BioTech_Pharma_Summit_Profile_1-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tAudrey Bonestebe\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Lab head Drug Product development of Biologics at Sanofi<\/h5>\n

\n\t\t\t\n\tChallenges of IV in-use stability for Biologics\n\t\t\t<\/a>\n\t<\/h3>\n\t

Audrey Bonestebe is an Industrial process engineer with specialization on pharmaceutical production and control. She has 16 years in pharmaceutical industry mainly in R&D 5 years in Biologics Formulation and DP development<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Ekkehard_Leberer_Sanofi_BioTech_Pharma_Summit_Profile_2.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Ekkehard_Leberer_Sanofi_BioTech_Pharma_Summit_Profile_2-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Ekkehard_Leberer_Sanofi_BioTech_Pharma_Summit_Profile_2-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Ekkehard_Leberer_Sanofi_BioTech_Pharma_Summit_Profile_2-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Ekkehard_Leberer_Sanofi_BioTech_Pharma_Summit_Profile_2-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Ekkehard_Leberer_Sanofi_BioTech_Pharma_Summit_Profile_2-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Ekkehard_Leberer_Sanofi_BioTech_Pharma_Summit_Profile_2-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33861″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/drug-delivery-formulation-2019-speakers\/ekkehard-leberer\/ekkehard_leberer_sanofi_biotech_pharma_summit_profile_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Ekkehard_Leberer_Sanofi_BioTech_Pharma_Summit_Profile_2.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"11","credit":"BENOIT RAJAU","camera":"NIKON D3S","caption":"","created_timestamp":"1403194376","copyright":"u00a9 Benoit RAJAU pour SANOFI.","focal_length":"85","iso":"250","shutter_speed":"0.008","title":"","orientation":"1"}” data-image-title=”Ekkehard_Leberer_Sanofi_BioTech_Pharma_Summit_Profile_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Ekkehard_Leberer_Sanofi_BioTech_Pharma_Summit_Profile_2-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Ekkehard_Leberer_Sanofi_BioTech_Pharma_Summit_Profile_2-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tEkkehard Leberer\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Senior Director, R&D Alliance Management at Sanofi<\/h5>\n

\n\t\t\t\n\tDelivering Biopharmaceuticals across Biobarriers: Opportunities and Challenges in Drug Development\n\t\t\t<\/a>\n\t<\/h3>\n\t

Dr. Ekkehard Leberer received his Ph.D. in Biology at the University of Konstanz, Germany (1986). His Ph.D. work in molecular biology of muscle development and disease was honoured with the Byk-Price of the Herbert Quandt-Stiftung of the Altana AG for its relevance in pharmaceutical research.<\/p>\n\t\t\t\t\t\t\t\"\"\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Eva-Maria-Knoch_Abbvie_BioTech_Pharma_Summit_Profile_1.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Eva-Maria-Knoch_Abbvie_BioTech_Pharma_Summit_Profile_1-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Eva-Maria-Knoch_Abbvie_BioTech_Pharma_Summit_Profile_1-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Eva-Maria-Knoch_Abbvie_BioTech_Pharma_Summit_Profile_1-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Eva-Maria-Knoch_Abbvie_BioTech_Pharma_Summit_Profile_1-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Eva-Maria-Knoch_Abbvie_BioTech_Pharma_Summit_Profile_1-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Eva-Maria-Knoch_Abbvie_BioTech_Pharma_Summit_Profile_1-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33856″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/drug-delivery-formulation-2019-speakers\/eva-maria-knoch\/eva-maria-knoch_abbvie_biotech_pharma_summit_profile_1\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Eva-Maria-Knoch_Abbvie_BioTech_Pharma_Summit_Profile_1.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"10","credit":"","camera":"Canon EOS 5D Mark II","caption":"","created_timestamp":"1333792782","copyright":"","focal_length":"168","iso":"100","shutter_speed":"0.008","title":"","orientation":"1"}” data-image-title=”Eva-Maria-Knoch_Abbvie_BioTech_Pharma_Summit_Profile_1″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Eva-Maria-Knoch_Abbvie_BioTech_Pharma_Summit_Profile_1-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Eva-Maria-Knoch_Abbvie_BioTech_Pharma_Summit_Profile_1-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tEva-Maria Knoch\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Senior Scientist I at AbbVie<\/h5>\n

\n\t\t\t\n\tThe challenge of low volumes – Implementation of low-consumption analytical methods for automated high throughput formulation screenings of biologics\n\t\t\t<\/a>\n\t<\/h3>\n\t

Eva-Maria Knoch is a Senior Scientist in NBE Drug Product Development at AbbVie Ludwigshafen. In 2013 and 2014 she was running her PostDoctoral studies at AbbVie, focused in Drug Product Development, NBE Formulation and Process Sciences. Since June 2014 she is working as a Senior Scientist at AbbVie, focusing in Drug Product Development, NBE Formulation Sciences.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Ijeoma_Uchegbu_Nanomerics_BioTech_Pharma_Summit_Profile_1.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Ijeoma_Uchegbu_Nanomerics_BioTech_Pharma_Summit_Profile_1-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Ijeoma_Uchegbu_Nanomerics_BioTech_Pharma_Summit_Profile_1-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Ijeoma_Uchegbu_Nanomerics_BioTech_Pharma_Summit_Profile_1-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Ijeoma_Uchegbu_Nanomerics_BioTech_Pharma_Summit_Profile_1-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Ijeoma_Uchegbu_Nanomerics_BioTech_Pharma_Summit_Profile_1-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Ijeoma_Uchegbu_Nanomerics_BioTech_Pharma_Summit_Profile_1-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33850″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/drug-delivery-formulation-2019-speakers\/ijeoma-uchegbu\/ijeoma_uchegbu_nanomerics_biotech_pharma_summit_profile_1\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Ijeoma_Uchegbu_Nanomerics_BioTech_Pharma_Summit_Profile_1.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"2.4","credit":"","camera":"iPhone X","caption":"","created_timestamp":"1554748887","copyright":"","focal_length":"6","iso":"125","shutter_speed":"0.04","title":"","orientation":"1"}” data-image-title=”Ijeoma_Uchegbu_Nanomerics_BioTech_Pharma_Summit_Profile_1″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Ijeoma_Uchegbu_Nanomerics_BioTech_Pharma_Summit_Profile_1-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Ijeoma_Uchegbu_Nanomerics_BioTech_Pharma_Summit_Profile_1-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tIjeoma Uchegbu\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Chief Scientific Officer at Nanomerics<\/h5>\n

\n\t\t\t\n\tDeveloping nano-enabled medicines\n\t\t\t<\/a>\n\t<\/h3>\n\t

Ijeoma Uchegbu is Professor of Pharmaceutical Nanoscience at the UCL School of Pharmacy, University College London (UCL), UCL\u2019s Pro-Vice Provost for Africa and The Middle East and Chief Scientific Officer of Nanomerics Ltd. Nanomerics is a UCL spin out company, which was founded by Ijeoma and Andreas G. Sch\u00e4tzlein (http:\/\/www.nanomerics.com\/).<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Isabel_Ottinger_BioTech_Pharma_Summit_Novartis_Profile_2.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Isabel_Ottinger_BioTech_Pharma_Summit_Novartis_Profile_2-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Isabel_Ottinger_BioTech_Pharma_Summit_Novartis_Profile_2-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Isabel_Ottinger_BioTech_Pharma_Summit_Novartis_Profile_2-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Isabel_Ottinger_BioTech_Pharma_Summit_Novartis_Profile_2-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Isabel_Ottinger_BioTech_Pharma_Summit_Novartis_Profile_2-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Isabel_Ottinger_BioTech_Pharma_Summit_Novartis_Profile_2-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33878″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/drug-delivery-formulation-2019-speakers\/isabel-ottinger\/isabel_ottinger_biotech_pharma_summit_novartis_profile_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Isabel_Ottinger_BioTech_Pharma_Summit_Novartis_Profile_2.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"1"}” data-image-title=”Isabel_Ottinger_BioTech_Pharma_Summit_Novartis_Profile_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Isabel_Ottinger_BioTech_Pharma_Summit_Novartis_Profile_2-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Isabel_Ottinger_BioTech_Pharma_Summit_Novartis_Profile_2-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tIsabel Ottinger\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Team Head Pharmaceutical Development Early Phase at Novartis Pharma AG<\/h5>\n

\n\t\t\t\n\tSustained delivery of biologics: From benchtop to patients\n\t\t\t<\/a>\n\t<\/h3>\n\t

Isabel Ottinger is Team Head Pharmaceutical Development for Novel Biologic Entities (NBE) Early Phase since February 2018. With her team, she is responsible for the execution of all early phase NBE drug product development programs from first clinical dosage forms to post-POC formulations. In addition, she and her group take care about several NBE Drug Delivery programs in different therapeutic indications as LCM as well as first clinical formulation. Prior to her current role, Isabel was Team Head Pharmaceutical Development from 2014 to 2018.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Korbinian_Loebmann_University_copenhagen_Zerion_BioTech_Pharma_Summit_Profile_1.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Korbinian_Loebmann_University_copenhagen_Zerion_BioTech_Pharma_Summit_Profile_1-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Korbinian_Loebmann_University_copenhagen_Zerion_BioTech_Pharma_Summit_Profile_1-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Korbinian_Loebmann_University_copenhagen_Zerion_BioTech_Pharma_Summit_Profile_1-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Korbinian_Loebmann_University_copenhagen_Zerion_BioTech_Pharma_Summit_Profile_1-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Korbinian_Loebmann_University_copenhagen_Zerion_BioTech_Pharma_Summit_Profile_1-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Korbinian_Loebmann_University_copenhagen_Zerion_BioTech_Pharma_Summit_Profile_1-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33844″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/drug-delivery-formulation-2019-speakers\/korbinian-loebmann\/korbinian_loebmann_university_copenhagen_zerion_biotech_pharma_summit_profile_1\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Korbinian_Loebmann_University_copenhagen_Zerion_BioTech_Pharma_Summit_Profile_1.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"1"}” data-image-title=”Korbinian_Loebmann_University_copenhagen_Zerion_BioTech_Pharma_Summit_Profile_1″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Korbinian_Loebmann_University_copenhagen_Zerion_BioTech_Pharma_Summit_Profile_1-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Korbinian_Loebmann_University_copenhagen_Zerion_BioTech_Pharma_Summit_Profile_1-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tKorbinian Lo\u0308bmann\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
CSO at Zerion, Assoc. Prof. at University of Copenhagen<\/h5>\n

\n\t\t\t\n\tSolubility increase of poorly soluble oral drugs using whey proteins as excipient\n\t\t\t<\/a>\n\t<\/h3>\n\t

Korbinian L\u00f6bmann has a strong track record in pharmaceutical formulation and drug delivery. He has 9 years of experience in solid formulation and dosage form development, including preformulation, formulation, processing and manufacturing together with the relevant solid state characterization and quality control.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lise_Vanderkelen_Nelson_Labs_BioTech_Pharma_Summit_Profile_1.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lise_Vanderkelen_Nelson_Labs_BioTech_Pharma_Summit_Profile_1-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lise_Vanderkelen_Nelson_Labs_BioTech_Pharma_Summit_Profile_1-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lise_Vanderkelen_Nelson_Labs_BioTech_Pharma_Summit_Profile_1-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lise_Vanderkelen_Nelson_Labs_BioTech_Pharma_Summit_Profile_1-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lise_Vanderkelen_Nelson_Labs_BioTech_Pharma_Summit_Profile_1-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lise_Vanderkelen_Nelson_Labs_BioTech_Pharma_Summit_Profile_1-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33838″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/drug-delivery-formulation-2019-speakers\/lise-vanderkelen\/lise_vanderkelen_nelson_labs_biotech_pharma_summit_profile_1\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lise_Vanderkelen_Nelson_Labs_BioTech_Pharma_Summit_Profile_1.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"5.6","credit":"","camera":"Canon EOS 100D","caption":"","created_timestamp":"1429612451","copyright":"","focal_length":"92","iso":"160","shutter_speed":"0.008","title":"","orientation":"1"}” data-image-title=”Lise_Vanderkelen_Nelson_Labs_BioTech_Pharma_Summit_Profile_1″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lise_Vanderkelen_Nelson_Labs_BioTech_Pharma_Summit_Profile_1-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lise_Vanderkelen_Nelson_Labs_BioTech_Pharma_Summit_Profile_1-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tLise Vanderkelen\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Department Head Pharma and Microbial Services at Nelson Labs NV.<\/h5>\n

\n\t\t\t\n\tDrug\/Device compatibility – Finding a Perfect match\n\t\t\t<\/a>\n\t<\/h3>\n\t

Lise Vanderkelen received her Ph.D. from the Faculty of Bioscience Engineering at the University of Leuven (Belgium) in 2012. She started at Nelson Labs Europe (formerly known as Toxikon Europe) in 2013 as study director Extractables & Leachables, focusing on parenteral applications and in 2014 she became responsible for the chemical characterization testing of medical devices (ISO 10993-18). In 2016, she became Department Head Pharma Services at Nelson Labs Europe.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Ramesh_Shanmugam_BioTech_Pharma_Summit_Astrazeneca_1.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Ramesh_Shanmugam_BioTech_Pharma_Summit_Astrazeneca_1-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Ramesh_Shanmugam_BioTech_Pharma_Summit_Astrazeneca_1-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Ramesh_Shanmugam_BioTech_Pharma_Summit_Astrazeneca_1-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Ramesh_Shanmugam_BioTech_Pharma_Summit_Astrazeneca_1-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Ramesh_Shanmugam_BioTech_Pharma_Summit_Astrazeneca_1-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Ramesh_Shanmugam_BioTech_Pharma_Summit_Astrazeneca_1-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33810″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/drug-delivery-formulation-2019-speakers\/ramesh-shanmugam\/ramesh_shanmugam_biotech_pharma_summit_astrazeneca_1\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Ramesh_Shanmugam_BioTech_Pharma_Summit_Astrazeneca_1.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"5.3","credit":"Rob Kennard","camera":"NIKON D810","caption":"","created_timestamp":"1464019573","copyright":"Rob Kennard","focal_length":"200","iso":"3200","shutter_speed":"0.01","title":"","orientation":"1"}” data-image-title=”Ramesh_Shanmugam_BioTech_Pharma_Summit_Astrazeneca_1″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Ramesh_Shanmugam_BioTech_Pharma_Summit_Astrazeneca_1-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Ramesh_Shanmugam_BioTech_Pharma_Summit_Astrazeneca_1-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tRamesh Shanmugam\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Scientist II at AstraZeneca<\/h5>\n

\n\t\t\t\n\tImpact of trace level of excipient impurity in drug product stability\n\t\t\t<\/a>\n\t<\/h3>\n\t

Ramesh Shanmugam is a Scientist II in Formulation Sciences at AstraZeneca, Cambridge. Being a Pharmaceutical Boo-technologist, he has over 12+ years of broad cross-functional industrial research experiences in drug product formulation, lyophilization process development, biophysical characterization and drug product manufacturing process development for both early, late stage biologics.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Sabine_Hauck_BioTech_Pharma_Summit_Leukocare.png 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Sabine_Hauck_BioTech_Pharma_Summit_Leukocare-201×300.png 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Sabine_Hauck_BioTech_Pharma_Summit_Leukocare-686×1024.png 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Sabine_Hauck_BioTech_Pharma_Summit_Leukocare-768×1146.png 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Sabine_Hauck_BioTech_Pharma_Summit_Leukocare-630×940.png 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Sabine_Hauck_BioTech_Pharma_Summit_Leukocare-420×627.png 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Sabine_Hauck_BioTech_Pharma_Summit_Leukocare-315×470.png 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33800″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/drug-delivery-formulation-2019-speakers\/sabine-hauck\/sabine_hauck_biotech_pharma_summit_leukocare\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Sabine_Hauck_BioTech_Pharma_Summit_Leukocare.png” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}” data-image-title=”Sabine_Hauck_BioTech_Pharma_Summit_Leukocare” data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Sabine_Hauck_BioTech_Pharma_Summit_Leukocare-201×300.png” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Sabine_Hauck_BioTech_Pharma_Summit_Leukocare-686×1024.png”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tSabine Hauck\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Vice President Research & Development at LEUKOCARE AG<\/h5>\n

\n\t\t\t\n\tArtificial intelligence and its application in biopharmaceutical formulation development\n\t\t\t<\/a>\n\t<\/h3>\n\t

Sabine Hauck is Vice President Research & Development at Munich-based biotech company Leukocare AG. She has experience of about 20 years in pharmaceutical development and has held various positions in the field of pharmaceutical development, quality assurance and regulatory affairs in small to midsize biotech and pharma companies respectively.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Shahid_Uddin_Immunocore_BioTech_Pharma_Summit_Drug_Delivery_Formulation_DDF_Munich_1.jpeg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Shahid_Uddin_Immunocore_BioTech_Pharma_Summit_Drug_Delivery_Formulation_DDF_Munich_1-201×300.jpeg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Shahid_Uddin_Immunocore_BioTech_Pharma_Summit_Drug_Delivery_Formulation_DDF_Munich_1-686×1024.jpeg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Shahid_Uddin_Immunocore_BioTech_Pharma_Summit_Drug_Delivery_Formulation_DDF_Munich_1-768×1146.jpeg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Shahid_Uddin_Immunocore_BioTech_Pharma_Summit_Drug_Delivery_Formulation_DDF_Munich_1-630×940.jpeg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Shahid_Uddin_Immunocore_BioTech_Pharma_Summit_Drug_Delivery_Formulation_DDF_Munich_1-420×627.jpeg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Shahid_Uddin_Immunocore_BioTech_Pharma_Summit_Drug_Delivery_Formulation_DDF_Munich_1-315×470.jpeg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33816″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/drug-delivery-formulation-2019-speakers\/shahid-uddin\/shahid_uddin_immunocore_biotech_pharma_summit_drug_delivery_formulation_ddf_munich_1\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Shahid_Uddin_Immunocore_BioTech_Pharma_Summit_Drug_Delivery_Formulation_DDF_Munich_1.jpeg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"1"}” data-image-title=”Shahid_Uddin_Immunocore_BioTech_Pharma_Summit_Drug_Delivery_Formulation_DDF_Munich_1″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Shahid_Uddin_Immunocore_BioTech_Pharma_Summit_Drug_Delivery_Formulation_DDF_Munich_1-201×300.jpeg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Shahid_Uddin_Immunocore_BioTech_Pharma_Summit_Drug_Delivery_Formulation_DDF_Munich_1-686×1024.jpeg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tShahid Uddin\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Director of Drug Product, Formulation & Stability at Immunocore<\/h5>\n

\n\t\t\t\n\tDevelopability assessment of biologics and formulation of novel molecule\n\t\t\t<\/a>\n\t<\/h3>\n\t

Shahid is the Director of Drug product, formulation & stability at Immunocore, responsible for development for antibody and peptide and therapeutics, encompassing new novel formats. Shahid has supervised over 20 Ph.D. and Postdocs, and his experience involves both early stage formulation development as well as late stage development as both liquid and lyophilized presentations. His group also have experience of several types of drug delivery technologies including discovery and protein engineering.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Tudor_Arvinte_University_Geneva_BioTech_Pharma_Summit_Profile_1.png 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Tudor_Arvinte_University_Geneva_BioTech_Pharma_Summit_Profile_1-201×300.png 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Tudor_Arvinte_University_Geneva_BioTech_Pharma_Summit_Profile_1-686×1024.png 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Tudor_Arvinte_University_Geneva_BioTech_Pharma_Summit_Profile_1-768×1146.png 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Tudor_Arvinte_University_Geneva_BioTech_Pharma_Summit_Profile_1-630×940.png 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Tudor_Arvinte_University_Geneva_BioTech_Pharma_Summit_Profile_1-420×627.png 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Tudor_Arvinte_University_Geneva_BioTech_Pharma_Summit_Profile_1-315×470.png 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33806″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/drug-delivery-formulation-2019-speakers\/tudor-arvinte\/tudor_arvinte_university_geneva_biotech_pharma_summit_profile_1\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Tudor_Arvinte_University_Geneva_BioTech_Pharma_Summit_Profile_1.png” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}” data-image-title=”Tudor_Arvinte_University_Geneva_BioTech_Pharma_Summit_Profile_1″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Tudor_Arvinte_University_Geneva_BioTech_Pharma_Summit_Profile_1-201×300.png” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Tudor_Arvinte_University_Geneva_BioTech_Pharma_Summit_Profile_1-686×1024.png”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tTudor Arvinte\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Professor at University of Geneva, Switzerland, CEO of Therapeomic<\/h5>\n

\n\t\t\t\n\tAchieve Stability, High Concentration, and Excellent Manufacturing Systems\n\t\t\t<\/a>\n\t<\/h3>\n\t

Tudor Arvinte studied physics at University of Jassy, Romania, and received his Ph.D. in biophysics from University of Du\u0308sseldorf, Germany. He held numerous research positions in Europe and the USA at: Max-Planck Institute, Germany; C.N.R.S., France; Cornell University, New York; Texas A&M University; Ciba-Geigy U.K., Novartis, Switzerland. T. Arvinte worked with more than 200 biopharmaceuticals, three of his formulations reached the market, has over 90 publications and 15 patents.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Tanja_Henzler_Merck_BioTEch_Pharma_Summit_Profile_2.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Tanja_Henzler_Merck_BioTEch_Pharma_Summit_Profile_2-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Tanja_Henzler_Merck_BioTEch_Pharma_Summit_Profile_2-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Tanja_Henzler_Merck_BioTEch_Pharma_Summit_Profile_2-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Tanja_Henzler_Merck_BioTEch_Pharma_Summit_Profile_2-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Tanja_Henzler_Merck_BioTEch_Pharma_Summit_Profile_2-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Tanja_Henzler_Merck_BioTEch_Pharma_Summit_Profile_2-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33832″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/drug-delivery-formulation-2019-speakers\/tanja-henzler\/tanja_henzler_merck_biotech_pharma_summit_profile_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Tanja_Henzler_Merck_BioTEch_Pharma_Summit_Profile_2.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"18","credit":"","camera":"Canon EOS 5D Mark III","caption":"","created_timestamp":"1452950315","copyright":"","focal_length":"55","iso":"100","shutter_speed":"0.008","title":"","orientation":"1"}” data-image-title=”Tanja_Henzler_Merck_BioTEch_Pharma_Summit_Profile_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Tanja_Henzler_Merck_BioTEch_Pharma_Summit_Profile_2-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Tanja_Henzler_Merck_BioTEch_Pharma_Summit_Profile_2-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tTanja Henzler\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Director Liquid Formulation R&D at Merck KGaA<\/h5>\n

\n\t\t\t\n\tViscosity and Aggregation – Challenges in Biomolecule Formulation\n\t\t\t<\/a>\n\t<\/h3>\n\t

Tanja Henzler studied Biology in T\u00fcbingen and received her PhD in Virology at the Ruprechts Karls University Heidelberg. In 2002 she joined Merck in Darmstadt, Germany. Tanja Henzler has a focus in protein characterization and protein analytics. After evaluating new technologies for Merck Life Science she was coordinating an interdisciplinary and cross-divisional innovation project.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Tanvir_Tabish_Takeda_BioTech_Pharma_Summit_Profile_1.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Tanvir_Tabish_Takeda_BioTech_Pharma_Summit_Profile_1-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Tanvir_Tabish_Takeda_BioTech_Pharma_Summit_Profile_1-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Tanvir_Tabish_Takeda_BioTech_Pharma_Summit_Profile_1-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Tanvir_Tabish_Takeda_BioTech_Pharma_Summit_Profile_1-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Tanvir_Tabish_Takeda_BioTech_Pharma_Summit_Profile_1-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Tanvir_Tabish_Takeda_BioTech_Pharma_Summit_Profile_1-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33827″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/drug-delivery-formulation-2019-speakers\/tanvir-tabish\/tanvir_tabish_takeda_biotech_pharma_summit_profile_1\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Tanvir_Tabish_Takeda_BioTech_Pharma_Summit_Profile_1.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"2.8","credit":"","camera":"NIKON D850","caption":"","created_timestamp":"1524569954","copyright":"","focal_length":"70","iso":"360","shutter_speed":"0.00625","title":"","orientation":"1"}” data-image-title=”Tanvir_Tabish_Takeda_BioTech_Pharma_Summit_Profile_1″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Tanvir_Tabish_Takeda_BioTech_Pharma_Summit_Profile_1-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Tanvir_Tabish_Takeda_BioTech_Pharma_Summit_Profile_1-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tTanvir Tabish\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Head of Formulation Development for Gene Therapy and Protein Modalities at Takeda<\/h5>\n

\n\t\t\t\n\tAn Intercompany Perspective on Biopharmaceutical Drug Product Robustness Studies | Lyophilisation of AAV Gene Therapy Product\n\t\t\t<\/a>\n\t<\/h4>\n\t

Tanvir Tabish joined Takeda about three years ago and is presently the Head of Formulation Development and Characterisation; Tanvir is currently based in Vienna, Austria. His responsibilities include developing stable formulations for various Gene Therapy and protein based modalities. Prior to joining Takeda, Tanvir worked as an Associate Director, for Beaufour Ipsen, and managed a trans-national Early and Pre-Formulation Development group with members based in Paris and Boston.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Wei_Tian_Lonza_BioTEch_Pharma_Summit_Profile_2.jpeg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Wei_Tian_Lonza_BioTEch_Pharma_Summit_Profile_2-201×300.jpeg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Wei_Tian_Lonza_BioTEch_Pharma_Summit_Profile_2-686×1024.jpeg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Wei_Tian_Lonza_BioTEch_Pharma_Summit_Profile_2-768×1146.jpeg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Wei_Tian_Lonza_BioTEch_Pharma_Summit_Profile_2-630×940.jpeg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Wei_Tian_Lonza_BioTEch_Pharma_Summit_Profile_2-420×627.jpeg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Wei_Tian_Lonza_BioTEch_Pharma_Summit_Profile_2-315×470.jpeg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33822″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/drug-delivery-formulation-2019-speakers\/wei-tian\/wei_tian_lonza_biotech_pharma_summit_profile_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Wei_Tian_Lonza_BioTEch_Pharma_Summit_Profile_2.jpeg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"1"}” data-image-title=”Wei_Tian_Lonza_BioTEch_Pharma_Summit_Profile_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Wei_Tian_Lonza_BioTEch_Pharma_Summit_Profile_2-201×300.jpeg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Wei_Tian_Lonza_BioTEch_Pharma_Summit_Profile_2-686×1024.jpeg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tWei Tian\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Director Formulation at Lonza<\/h5>\n

\n\t\t\t\n\tLipid based formulation for enhanced bioavailability\n\t\t\t<\/a>\n\t<\/h3>\n\t

Wei Tian is an experienced pharmaceutical development professional and has achieved market authorization of several generic and NCE products in the EU and US. Many of these products were approved through the 505(b)2 application route, through reformulation and dosage changes.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/YASEMIN_KARANIS_IQVIA_DDF_2019_1.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/YASEMIN_KARANIS_IQVIA_DDF_2019_1-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/YASEMIN_KARANIS_IQVIA_DDF_2019_1-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/YASEMIN_KARANIS_IQVIA_DDF_2019_1-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/YASEMIN_KARANIS_IQVIA_DDF_2019_1-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/YASEMIN_KARANIS_IQVIA_DDF_2019_1-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/YASEMIN_KARANIS_IQVIA_DDF_2019_1-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33793″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/drug-delivery-formulation-2019-speakers\/yasemin-karanis\/yasemin_karanis_iqvia_ddf_2019_1\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/YASEMIN_KARANIS_IQVIA_DDF_2019_1.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"1"}” data-image-title=”YASEMIN_KARANIS_IQVIA_DDF_2019_1″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/YASEMIN_KARANIS_IQVIA_DDF_2019_1-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/YASEMIN_KARANIS_IQVIA_DDF_2019_1-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tYasemin Karanis\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Consultant, Thought Leadership at IQVIA<\/h5>\n

\n\t\t\t\n\tGlobal Pharma Trends & Opportunities for the Packaging Industry\n\t\t\t<\/a>\n\t<\/h3>\n\t

Yasemin is a Consultant in the European Thought Leadership team based in IQVIA\u2019s London office. Her primary areas of focus are; trends in innovative launches as well as the oncology market with an emphasis on clinical and commercial trends.<\/p>\n

Yasemin holds a Masters in Cancer Research and a Bachelor of Science degree in Biomedical Sciences both from Newcastle University. Prior to her role in Thought Leadership, Yasemin was part of the Real-World Insights \u2013 Global Oncology a team where she worked on the co-ordination and set-up of reports focusing on various cancers.<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

Our Speakers (A-Z) Audrey Bonestebe Lab head Drug Product development of Biologics at Sanofi Challenges of IV in-use stability for Biologics Audrey Bonestebe is an Industrial process engineer with specialization on pharmaceutical production and control. She has 16 years in pharmaceutical industry mainly in R&D 5 years in Biologics Formulation and DP development Eva-Maria Knoch…<\/p>\n","protected":false},"author":1,"featured_media":31757,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"inline_featured_image":false,"footnotes":""},"class_list":["post-33788","page","type-page","status-publish","has-post-thumbnail","hentry"],"yoast_head":"\nDrug Delivery & Formulation 2019 Speakers • BioTech Pharma Summit<\/title>\n<meta name=\"description\" content=\"On 19 & 20 September 2019, Munich (Germany) we have hosted the BioTech Pharma Summit: Drug Delivery & Formulation 2019 conference.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/drug-delivery-formulation-2019-speakers\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Drug Delivery & Formulation 2019 Speakers • BioTech Pharma Summit\" \/>\n<meta property=\"og:description\" content=\"On 19 & 20 September 2019, Munich (Germany) we have hosted the BioTech Pharma Summit: Drug Delivery & Formulation 2019 conference.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.biotechpharmasummit.com\/index.php\/drug-delivery-formulation-2019-speakers\/\" \/>\n<meta property=\"og:site_name\" content=\"BioTech Pharma Summit\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/biotechpharmasummit\/\" \/>\n<meta property=\"article:modified_time\" content=\"2021-03-19T09:03:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/06\/DDF_Drug_Delivery_Formulation_Summit_Munich_2019_Banner.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"993\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@biotechsummit\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"11 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/drug-delivery-formulation-2019-speakers\/\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/drug-delivery-formulation-2019-speakers\/\",\"name\":\"Drug Delivery & Formulation 2019 Speakers • BioTech Pharma Summit\",\"isPartOf\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/drug-delivery-formulation-2019-speakers\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/drug-delivery-formulation-2019-speakers\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/06\/DDF_Drug_Delivery_Formulation_Summit_Munich_2019_Banner.png\",\"datePublished\":\"2020-08-27T15:58:42+00:00\",\"dateModified\":\"2021-03-19T09:03:57+00:00\",\"description\":\"On 19 & 20 September 2019, Munich (Germany) we have hosted the BioTech Pharma Summit: Drug Delivery & Formulation 2019 conference.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/drug-delivery-formulation-2019-speakers\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.biotechpharmasummit.com\/index.php\/drug-delivery-formulation-2019-speakers\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/drug-delivery-formulation-2019-speakers\/#primaryimage\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/06\/DDF_Drug_Delivery_Formulation_Summit_Munich_2019_Banner.png\",\"contentUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/06\/DDF_Drug_Delivery_Formulation_Summit_Munich_2019_Banner.png\",\"width\":1920,\"height\":993},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/drug-delivery-formulation-2019-speakers\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.biotechpharmasummit.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Drug Delivery & Formulation 2019 Speakers\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#website\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/\",\"name\":\"BioTech Pharma Summit\",\"description\":\"The Tomorrow's healthcare congress\",\"publisher\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.biotechpharmasummit.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#organization\",\"name\":\"EPM Group\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png\",\"contentUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png\",\"width\":2000,\"height\":2000,\"caption\":\"EPM Group\"},\"image\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/biotechpharmasummit\/\",\"https:\/\/x.com\/biotechsummit\",\"https:\/\/www.instagram.com\/biotechpharmasummit\/\",\"https:\/\/www.linkedin.com\/company\/biotech-pharma-summit\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Drug Delivery & Formulation 2019 Speakers • BioTech Pharma Summit","description":"On 19 & 20 September 2019, Munich (Germany) we have hosted the BioTech Pharma Summit: Drug Delivery & Formulation 2019 conference.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.biotechpharmasummit.com\/index.php\/drug-delivery-formulation-2019-speakers\/","og_locale":"en_US","og_type":"article","og_title":"Drug Delivery & Formulation 2019 Speakers • BioTech Pharma Summit","og_description":"On 19 & 20 September 2019, Munich (Germany) we have hosted the BioTech Pharma Summit: Drug Delivery & Formulation 2019 conference.","og_url":"https:\/\/www.biotechpharmasummit.com\/index.php\/drug-delivery-formulation-2019-speakers\/","og_site_name":"BioTech Pharma Summit","article_publisher":"https:\/\/www.facebook.com\/biotechpharmasummit\/","article_modified_time":"2021-03-19T09:03:57+00:00","og_image":[{"width":1920,"height":993,"url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/06\/DDF_Drug_Delivery_Formulation_Summit_Munich_2019_Banner.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@biotechsummit","twitter_misc":{"Est. reading time":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/drug-delivery-formulation-2019-speakers\/","url":"https:\/\/www.biotechpharmasummit.com\/index.php\/drug-delivery-formulation-2019-speakers\/","name":"Drug Delivery & Formulation 2019 Speakers • BioTech Pharma Summit","isPartOf":{"@id":"https:\/\/www.biotechpharmasummit.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/drug-delivery-formulation-2019-speakers\/#primaryimage"},"image":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/drug-delivery-formulation-2019-speakers\/#primaryimage"},"thumbnailUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/06\/DDF_Drug_Delivery_Formulation_Summit_Munich_2019_Banner.png","datePublished":"2020-08-27T15:58:42+00:00","dateModified":"2021-03-19T09:03:57+00:00","description":"On 19 & 20 September 2019, Munich (Germany) we have hosted the BioTech Pharma Summit: Drug Delivery & Formulation 2019 conference.","breadcrumb":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/drug-delivery-formulation-2019-speakers\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.biotechpharmasummit.com\/index.php\/drug-delivery-formulation-2019-speakers\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/drug-delivery-formulation-2019-speakers\/#primaryimage","url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/06\/DDF_Drug_Delivery_Formulation_Summit_Munich_2019_Banner.png","contentUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/06\/DDF_Drug_Delivery_Formulation_Summit_Munich_2019_Banner.png","width":1920,"height":993},{"@type":"BreadcrumbList","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/drug-delivery-formulation-2019-speakers\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.biotechpharmasummit.com\/"},{"@type":"ListItem","position":2,"name":"Drug Delivery & Formulation 2019 Speakers"}]},{"@type":"WebSite","@id":"https:\/\/www.biotechpharmasummit.com\/#website","url":"https:\/\/www.biotechpharmasummit.com\/","name":"BioTech Pharma Summit","description":"The Tomorrow's healthcare congress","publisher":{"@id":"https:\/\/www.biotechpharmasummit.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.biotechpharmasummit.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.biotechpharmasummit.com\/#organization","name":"EPM Group","url":"https:\/\/www.biotechpharmasummit.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png","contentUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png","width":2000,"height":2000,"caption":"EPM Group"},"image":{"@id":"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/biotechpharmasummit\/","https:\/\/x.com\/biotechsummit","https:\/\/www.instagram.com\/biotechpharmasummit\/","https:\/\/www.linkedin.com\/company\/biotech-pharma-summit\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/33788","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/comments?post=33788"}],"version-history":[{"count":4,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/33788\/revisions"}],"predecessor-version":[{"id":36096,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/33788\/revisions\/36096"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/media\/31757"}],"wp:attachment":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/media?parent=33788"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}